Morgan Stanley Sticks to Its Hold Rating for BioNTech SE (BNTX)
HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $113 Price Target
BioNTech Analyst Ratings
JPMorgan raised the target price of Biontech to $94.
BioNTech Analyst Ratings
HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $113 Price Target
BioNTech Analyst Ratings
BioNTech Analyst Ratings
BioNTech Analyst Ratings
BioNTech Analyst Ratings
HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $113 Price Target
Reiterating Buy on BioNTech Amid Strategic Growth and Upcoming Catalysts
Critical Insights From BioNTech Analyst Ratings: What You Need To Know
HC Wainwright & Co. : The BioNTech (BNTX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $113.00.
BioNTech Analyst Ratings
Analysts Conflicted on These Healthcare Names: Nektar Therapeutics (NKTR) and BioNTech SE (BNTX)
Buy Rating on BioNTech SE Amidst Undervaluation and Strong Pipeline Prospects
BioNTech SE: Leerink Partners cuts price target from $116 to $102
Evercore ISI's initial price target for BioNTech is $100
BioNTech (BNTX.US) was first covered by Evercore ISI Group, which gave the market a simultaneous rating, with a target price of $100.00.